Advertisement

Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass

      Abstract

      The anatomic and physiologic changes in the gastrointestinal (GI) tract after bariatric surgery may significantly affect the pharmacokinetics of medications taken by the patients for various reasons. Unfortunately, there is little information regarding changes in drug absorption after bariatric surgeries, limiting the ability of medical professionals to produce clear recommendations on what changes should be made to the formulations and dosing regimens of drugs after bariatric surgery. In this article, we report and analyze a case of 52-year-old male patient with morbid obesity and attention-deficit/hyperactivity disorder (ADHD) who experienced lack of methylphenidate efficacy after Roux en-Y gastric bypass (RYGB), which was eventually resolved by using the transdermal patch instead of an oral product. Interestingly, in the same patient, a prior gastric band had no effect on the drug’s efficacy. Especially in light of a recent case report of methylphenidate toxicity after RYGB, these 2 cases suggest that bariatric surgeries may alter the absorption of orally administered methylphenidate in an unpredictable manner; hence, it is prudent to closely monitor the therapeutic/toxic effects of methylphenidate after bariatric surgery, and to be aware of nonoral treatment options of this medication.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Azran C.
        • Wolk O.
        • Zur M.
        • et al.
        Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations.
        Obes Rev. 2016; 17: 1050-1066
        • Epstein T.
        • Patsopoulos N.A.
        • Weiser M.
        Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
        Cochrane Database Syst Rev. 2014; (Art. No.: CD005041)
        • Cortese S.
        • Moreira-Maia C.
        • St Fleur D.
        • Faraone S.V.
        Association between ADHD and obesity: a systematic review and meta-analysis.
        Am J Psychiatry. 2016; 173: 34-43
        • Polanczyk G.
        • de Lima M.
        • Horta B.L.
        • Biederman J.
        • Rohde L.A.
        The worldwide prevalence of ADHD: A systematic review and metaregression analysis.
        Am J Psychiatry. 2007; 164: 942-948
        • Ludvigsson M.
        • Haenni A.
        Methylphenidate toxicity after Roux-en-Y gastric bypass.
        Surg Obes Relat Dis. 2016; 12: e55-e57
        • Seaman J.S.
        • Bowers S.P.
        • Dixon P.
        • Schindler L.
        Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model.
        Psychosomatics. 2005; 46: 250-253
        • Beig A.
        • Miller J.M.
        • Lindley D.
        • Dahan A.
        Striking the optimal solubility–permeability balance in oral formulation development for lipophilic drugs: Maximizing carbamazepine blood levels.
        Mol Pharm. 2017; 14: 319-327
        • Matsui K.
        • Tsume Y.
        • Amidon G.E.
        • Amidon G.L.
        The evaluation of in vitro drug dissolution of commercially available oral dosage forms for itraconazole in gastrointestinal simulator with biorelevant media.
        J Pharm Sci. 2016; 105: 2804-2814
        • Skottheim I.B.
        • Jakobsen G.S.
        • Stormark K.
        • et al.
        Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch.
        Clin Pharmacol Ther. 2010; 87: 699-705